Aviso: Este sitio agrega datos públicos oficiales de la FDA, ClinicalTrials.gov, PubMed y SEC EDGAR solo como referencia general. No constituye asesoramiento médico, diagnóstico, recomendaciones de tratamiento ni asesoramiento de inversión.

PubMed

Characteristics of pivotal clinical trials of FDA-approved endovascular devices between 2000 and 2018: An interrupted time series analysis.

PMID: 37008598 ·

J, o, h, n, , T, , M, o, o, n, ;, , M, e, n, e, l, a, o, s, , K, o, n, s, t, a, n, t, i, n, i, d, i, s, ;, , N, e, v, o, n, , S, o, n, g, ;, , N, a, r, i, m, a, n, , N, e, z, a, m, i, ;, , B, i, l, l, , S, , M, a, j, d, a, l, a, n, y, ;, , A, l, l, e, n, , H, e, r, r, ;, , G, a, r, y, , S, i, s, k, i, n

RevistaJournal of clinical and translational science
Año
PMID37008598

Resumen

The Food and Drug Administration (FDA) reviews safety, efficacy, and the quality of medical devices through its regulatory process. The FDA Safety and Innovation Act (FDASIA) of 2012 was aimed at accelerating the regulatory process for medical devices. The purpose of our study was to (1) quantify characteristics of pivotal clinical trials (PCTs) supporting the premarket approval of endovascular medical devices and (2) analyze trends over the last two decades in light of the FDASIA. We surveyed t

Fuente oficial

Ver en PubMed →

Datos obtenidos de PubMed / NCBI. Para consultar el texto completo y la información más reciente, remítase siempre al registro oficial.

↑